A phase II study to evaluate the efficacy, safety, and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer.

Trial Profile

A phase II study to evaluate the efficacy, safety, and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Lapatinib; Paclitaxel
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 23 Jul 2007 Updated status from NCT.
    • 20 Dec 2006 Info added from 1060015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top